Some potential side effects may include allergic reactions, injection site pain, or gastrointestinal disturbances
For research use only not for human consumption
Resources Sitohang, I
Notable FDA decisions expected for third quarter 2024 include several firsts: First psychedelic-assisted therapy for post-traumatic stress disorder (PTSD) First SC version of Ocrevus First new options for Niemann-Pick disease type C First new mechanism for gastroparesis First new mechanism to treat schizophrenia in decades Maryam Tabatabai Vice President, Clinical Information Editorial team Maryam Tabatabai Editor-In-Chief Vice President, Clinical Information Carole Kerzic, RPh Executive Editor Clinical Pharmacist, Drug Information Nicole Kjesbo, PharmD, BCPS Executive Editor Clinical Program Director, Pipeline Andrea Henry, PharmD, MBA, BCPS Specialty Drug Information Pharmacist Katie Lockhart Senior Manager, Analytics Olivia Pane, PharmD, CDCES Clinical Pharmacist, Drug Information Michelle E
Mid-protocol check (week 4-6): Retest IGF-1, fasting insulin, and fasting glucose
BKN combines with histamine to produce low volume low flow POTS